This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRTK Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Paratek Pharmaceuticals Stock (NASDAQ:PRTK) 30 days 90 days 365 days Advanced Chart Get PRTK alerts:Sign Up Key Stats Today's Range$2.23▼$2.2350-Day Range$2.17▼$2.2352-Week Range$1.29▼$3.65VolumeN/AAverage Volume724,253 shsMarket Capitalization$127.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewParatek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.Read More… Receive PRTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTK Stock News HeadlinesHow a Bucks County firm's multiyear pursuit of a partner led to a potential $330M dealApril 11, 2025 | bizjournals.comParatek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025April 10, 2025 | globenewswire.comTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionApril 18, 2025 | Crypto 101 Media (Ad)Paratek Pharmaceuticals to acquire Optinose in $330M transactionMarch 21, 2025 | markets.businessinsider.comOptinose Shares Surge Premarket on Takeover Deal With ParatekMarch 20, 2025 | marketwatch.comParatek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing CapabilitiesNovember 14, 2024 | globenewswire.comParatek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary DiseaseNovember 8, 2024 | globenewswire.comParatek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024October 14, 2024 | globenewswire.comSee More Headlines PRTK Stock Analysis - Frequently Asked Questions How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) announced its earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.08. The specialty pharmaceutical company earned $24.45 million during the quarter, compared to analyst estimates of $22.98 million. What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Paratek Pharmaceuticals investors own include Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), Verastem (VSTM), Citius Pharmaceuticals (CTXR), SCYNEXIS (SCYX) and Aurinia Pharmaceuticals (AUPH). Company Calendar Last Earnings11/08/2021Today4/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CIK1178711 Webwww.paratekpharma.com Phone(617) 807-6600Fax617-275-0039Employees268Year Founded1996Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,570,000.00 Net Margins-35.44% Pretax Margin-35.35% Return on EquityN/A Return on Assets-40.05% Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.46 Sales & Book Value Annual Sales$160.27 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.08) per share Price / Book-0.72Miscellaneous Outstanding Shares57,320,000Free Float52,736,000Market Cap$127.82 million OptionableOptionable Beta1.70 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:PRTK) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paratek Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Paratek Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.